AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with ... - Yahoo Finance
| AB Stock | EUR 0.78 0.01 1.27% |
About 61% of AB Science's investor base is looking to short. The analysis of current outlook of investing in AB Science SA suggests that many traders are alarmed regarding AB Science's prospects. The current market sentiment, together with AB Science's historical and current headlines, can help investors time the market. In addition, many technical investors use AB Science SA stock news signals to limit their universe of possible portfolio assets.
AB Science |
AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with ... Yahoo Finance
Read at news.google.com
 |
AB Science Fundamental Analysis
We analyze AB Science's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AB Science using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AB Science based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
AB Science is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
AB Science SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with AB Science stock to make a market-neutral strategy. Peer analysis of AB Science could also be used in its relative valuation, which is a method of valuing AB Science by comparing valuation metrics with similar companies.
Peers
AB Science Related Equities
| NANO | Nanobiotix | 10.36 | ||||
| IPH | Innate Pharma | 8.82 | ||||
| GNFT | Genfit | 0.55 | ||||
| ADOC | Adocia | 0.44 |
Complementary Tools for AB Science Stock analysis
When running AB Science's price analysis, check to measure AB Science's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AB Science is operating at the current time. Most of AB Science's value examination focuses on studying past and present price action to predict the probability of AB Science's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AB Science's price. Additionally, you may evaluate how the addition of AB Science to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |